Research Article
Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia
Figure 2
Kaplan–Meier curves of the survival times of de novo non-M3 AML patients. (a, b) OS and DFS of patients in CD56-high () and CD56-low () groups. (c, d) OS and DFS of patients administered bone marrow transplantation (BMT) () or not (Without BMT) (). (e, f) OS and DFS of different ELN risk groups (, ).
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |